Hydrophobic active agent particle coatings and methods for treatment

1. A device having a drug delivery coating comprising

(a) a first coated layer comprising (a1) a non-ionic polymer comprising one or more chemical groups selected from the group consisting of amides, ethers, and alcohols, and (a2) photoreactive groups, wherein the photoreactive groups are pendent from the non-ionic polymer or, when present, from a cross-linking agent, wherein the cross-linking agent comprises at least two photoreactive groups, or both;

(b) a second coated layer that is in direct contact with the first coated layer, the second coated layer comprising an acid polymer, wherein the first coated layer is between the second coated layer and a device surface, and wherein the acid polymer is present in the second coated layer in an amount greater than 90% (wt) of a total polymeric content of the second coated layer;

(c) a particle comprising a hydrophobic therapeutic agent; and

(d) a cationic agent;

wherein the cationic agent is associated with the particle, and the particle is within the second coated layer, associated with an outer surface of the second coated layer, or associated with an optional coated layer that is outer to the second coated layer, wherein the device surface to the second coated layer represents an inner to outer direction, respectively.

2. The device of claim 1 wherein the non-ionic polymer comprises an amide group that is a tertiary amide group, or the non-ionic polymer, comprises an amide group that is part of a lactam group.

3. The device of claim 1 wherein the acid polymer in the second coated layer is an acrylic acid polymer.

4. The device of claim 1 wherein the particle comprising the hydrophobic therapeutic agent and the cationic agent form coated therapeutic agent particles.

5. The device of claim 1 comprising a material on which the drug delivery coating is formed, wherein the material is selected from the group consisting of polyamide, polyimide, polyether block amide (PEBAX), polyether ether ketone (PEEK), high density polyethylene (HDPE), polyethylene, polyurethane, polyethylene vinyl acetate, polyethylene, styrene-butadiene copolymers, polyisoprene, isobutylene-isoprene copolymers (butyl rubber), butadiene-styrene-acrylonitrile copolymers, silicone polymers, fluorosilicone polymers, polycarbonates, polyesters, polyvinyl chloride, polyether-polyester copolymers, and polyether-polyamide copolymers.

6. The device of claim 1 comprising a catheter.

7. The device of claim 1 wherein the drug delivery coating is formed on a balloon surface of a balloon catheter.

8. The device of claim 1 wherein the non-ionic polymer is selected from the groups consisting of poly(N-vinyl caprolactam), poly-(vinyl pyrrolidone), poly(vinyl methyl ether), polyacrylamide, poly(N-isopropylacrylamide), poly(N,N-dimethylacrylamide), poly(vinyl alcohol) (PVA), poly(2-hydroxyethyl vinyl ether) PHEVE), poly(2-ethyl-2-oxazoline) (PEOX), poly(n-acetyliminoethylene) (PAIE), methyl cellulose, hydroxypropylcellulose, and hydroxyethylcellulose.

9. The device of claim 1 wherein the acid polymer is present in the second coated layer in an amount greater than 95% (wt) of the total polymeric content of the second coated layer.

10. The device of claim 1 wherein the particle is within the second coated layer or associated with an outer surface of the second coated layer.

11. The device of claim 1 wherein the non-ionic polymer is a vinyl pyrrolidone polymer.

12. The device of claim 11 wherein the vinyl pyrrolidone polymer comprises pendent photoreactive groups.

13. The device of claim 1 wherein first coated layer comprises a crosslinking agent comprising pendent photoreactive groups.

14. The device of claim 13 wherein the crosslinking agent is selected from the group consisting of:

wherein R 1 , R 2 , R 8 and R 9 are any substitution; R 3 , R 4 , R 6 and R 7 are alkyl, aryl, or a combination thereof; R 5 is any substitution; and each X, independently, is O, N, Se, S, or alkyl, or a combination thereof;

wherein R 1 and R 5 are any substitution; R 2 and R 4 can be any substitution, except OH; R 3 can be alkyl, aryl, or a combination thereof; and each X, independently, is O, N, Se, S, alkyl or a combination thereof;

wherein R 1 , R 2 , R 4 and R 5 are any substitution; R 3 is any substitution; R 6 and R 7 are alkyl, aryl, or a combination thereof; and each X, independently, is O, N, Se, S, alkyl, or a combination thereof; and

15. The coating of claim 14 wherein the cross-linking agent(s) is sodium bis(4-benzoylphenyl) phosphate.

16. The device of claim 1 wherein the hydrophobic therapeutic agent is a macrolide or a taxane.

17. The device of claim 16 wherein the macrolide is selected from the group consisting of rapamycin, everolimus, pimecrolimus, temsirolimus, tacrolimus, deforolimus, zotarolimus, and biolimus.

18. The device of claim 1 wherein the cationic agent is selected from the group consisting of cationic lipids, neutral lipids with cationic groups, and cationic polymers.

19. The device of claim 18 wherein the cationic agent is selected from the group consisting of polyethyleneimine and 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP).

20. The device of claim 1 wherein the non-ionic polymer is present in an amount of 75% wt or greater of a total polymeric content of the first coated layer.

21. The device of claim 20 wherein the non-ionic polymer is present in an amount in the range of 90% wt to 100% wt of the total polymeric content of the first coated layer.

22. A method for providing a therapeutic agent to a subject comprising inserting the device of claim 1 into the subject that is a patient, wherein the therapeutic agent is released to the patient to provide a therapeutic effect.